Physician profile
Robert A Hardy
NPI 1346450418
$8,281.38
in general payments reported to CMS, 2019-2025
35 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2021: $1,446 · 2022: $1,086 · 2023: $1,402 · 2024: $2,368 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,318.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $977.68 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $971.10 | 2021-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.47 | 2021-2025 | Jardiance, Ofev |
| Abbvie INC. | $900.35 | 2021-2025 | |
| Lilly USA, LLC | $780.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $763.03 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $525.08 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $329.10 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $227.76 | 2021-2024 | Spravato |
| Exact Sciences Corporation | $201.78 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $189.92 | 2021 | |
| Allergan, INC. | $181.69 | 2019 | |
| Merck Sharp & Dohme LLC | $177.00 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $165.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2019 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.